Tucatinib Combination in HER2-Positive Metastatic Breast Cancer: HER2CLIMB Trial
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On December 11, 2019, Rashmi K. Murthy and colleagues published the results of the HER2CLIMB Phase 2 clinical trial in The New England Journal of Medicine. The study evaluated the efficacy and safety of Tucatinib, an oral HER2-specific tyrosine kinase inhibitor, in combination with Trastuzumab and Capecitabine for patients with pretreated HER2-positive metastatic breast cancer.
Study Design: HER2CLIMB Trial
The trial randomized 612 patients with pretreated HER2-positive metastatic breast cancer in a 2:1 ratio:
- Tucatinib Group (N=410): Tucatinib (300 mg twice daily) + Trastuzumab + Capecitabine.
- Placebo Group (N=202): Placebo + Trastuzumab + Capecitabine.
A unique feature of this trial was the inclusion of patients with stable or active/progressing brain metastases.
Key Survival Results
Total Population
- Median Progression-Free Survival (PFS): 7.8 months for the Tucatinib group vs. 5.6 months for the placebo group (Hazard Ratio [HR] = 0.54).
- 1-Year PFS Rate: 33.1% (Tucatinib) vs. 12.3% (Placebo).
- Median Overall Survival (OS): 21.9 months (Tucatinib) vs. 17.4 months (Placebo) (HR = 0.66).
Patients with Brain Metastases
- Median PFS: 7.6 months (Tucatinib) vs. 5.4 months (Placebo).
- Risk Reduction: The addition of Tucatinib reduced the risk of disease progression or death by 52% in patients with brain metastases.
Safety Profile
The incidence of Grade 3 or higher adverse events was 55.2% in the Tucatinib group and 48.7% in the placebo group. Common side effects in the Tucatinib group included diarrhea (80.9%), palmar-plantar erythrodysesthesia (hand-foot syndrome, 63.4%), and nausea (58.4%). Most were manageable with supportive care or dose modifications.
Conclusion
The HER2CLIMB trial results establish that the combination of Tucatinib, Trastuzumab, and Capecitabine significantly improves both progression-free and overall survival in patients with pretreated HER2-positive metastatic breast cancer, including those with brain metastases, providing a vital new treatment option for this population.
Source: The New England Journal of Medicine - HER2CLIMB Trial Results
#BreastCancer #HER2Positive #Tucatinib #BrainMetastases #HER2CLIMB #CancerResearch
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4